While interventions that only target eRF1 may not be sufficient to provide a therapeutic benefit for many genetic diseases, the success of multi-drug combinations for CFTR modulator therapy for individuals with a F508del allele has established that addressing the molecular defects of CFTR protein misfolding, trafficking and activation can have a profound impact on overall CFTR activity. Here, ETF1 is linked to hereditary disease.